Breast Cancer Recurrence DNA Assay In Development; Exagen Targets HCV
This article was originally published in The Gray Sheet
Executive Summary
Exagen Diagnostics is working with FDA to design a pivotal trial assessing whether results from an earlier study of the firm's breast cancer recurrence genomic test can be duplicated in a larger cohort
You may also be interested in...
Exagen Files First Of Six Planned 510(k)s For Genomic Test Kits
Exagen Diagnostics recently filed the first of six planned 510(k) applications for test kits developed using its novel Coperna computational platform, kicking off a major push into the nascent genomic test kit market
Exagen Files First Of Six Planned 510(k)s For Genomic Test Kits
Exagen Diagnostics recently filed the first of six planned 510(k) applications for test kits developed using its novel Coperna computational platform, kicking off a major push into the nascent genomic test kit market
FDA Approves Another Chemotherapy Assay, First Monoclonal Her-2/neu Test
BioGenex's February launch of its InSite Her-2/neu monoclonal antibody kit for breast cancer detection will be supported by 12 U.S. sales reps